What Pheiron does

Pheiron is an applied AI lab building proprietary models that underwrite biology risk in drug development. The company was founded in 2023 and operates with a small team of eight from dual headquarters in New York and Berlin, incorporated in Delaware as Pheiron Inc. It is backed by four specialist VCs: Ananda, Compound, Fusion Fund, and Hummingbird, with a single disclosed $4.2M funding round from Compound in June 2025.

The company's core product is the Pheiron Prediction Platform, which delivers two calibrated outputs for selected upcoming clinical trial readouts: a Biological Support score measuring the quality of underlying biology for a drug program, and a Probability of Trial Success estimate derived from Monte Carlo simulations across trial endpoints. Underlying these outputs are proprietary models trained on multimodal human population data spanning genetics, -omics, clinical records, and observational and interventional cohorts covering millions of lives. Pheiron runs primary analyses directly on this data to diligence novel mechanisms, rather than synthesizing existing literature. The company claims ~20x enrichment for successful programs over the base rate on historical target-indication phase transitions, compared to ~2x for human genetic support alone, and publishes predictions prospectively before readouts to enable industry benchmarking. Twenty predictions are publicly documented, with indications spanning Parkinson's disease, ulcerative colitis, and obesity.

Pheiron operates a B2B subscription model targeting biotech and pharmaceutical drug developers and biotech capital allocators, who use the platform to select winning programs, price biology risk, and identify mispriced opportunities. No pricing has been publicly disclosed, and no enterprise customers are named; the platform currently appears to function primarily through partnership arrangements. In addition to serving external partners, Pheiron states that it uses its own biological alpha to select and develop proprietary drug programs, extending from analytics into upstream drug development economics.

Name

Pheiron

Legal name

Pheiron Inc.

Website

https://pheiron.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

Pheiron is an applied AI lab that builds proprietary models on multimodal human population data to underwrite biology risk and predict clinical trial success for biotech and pharma drug developers and biotech capital allocators.

Ownership category

akta.pro rank

Product category

AI Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Software Publishers (5132)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Clinical Pharmacology & Pharmacometrics (Modeling & Simulation) (HLAIALAG), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)

Keywords

• AI drug discovery
• Clinical trial predictions
• Biology risk underwriting
• Pharmaceutical analytics
• Biotech investment analysis

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations

Revenue model

1. Platform Access and Analysis Services: B2B platform providing biological alpha analysis to biotech/pharma companies, capital allocators, and drug developers. Partners use the platform to identify mispriced biology opportunities, select winning programs, and inform investment decisions. The company selects and develops its own drug programs using the edge.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Pheiron operates an applied AI platform that builds proprietary models and runs primary analyses on large-scale multimodal human data (genetics, -omics, clinical records, observational and interventional cohorts) to underwrite biology risk in drug development. It publishes prospective predictions on upcoming clinical trial readouts, providing calibrated Biological Support scores and probability of trial success estimates that biotech, pharma, and capital allocators use to select high-probability drug programs. The company also uses its own edge to select and internally develop drug programs with the highest probability of success.

Product overview

Pheiron is an applied AI lab offering a prediction platform for biological alpha in drug development. The core product consists of their clinical trial prediction platform that delivers Biological Support scores and Probability of Success metrics for upcoming clinical readouts. Users access the platform through their website where they can view published predictions on trials across various therapeutic areas including Parkinson's disease, ulcerative colitis, obesity, and other indications.

Differentiator

Problem solved

Functional benefit

Products and services

• Pheiron Prediction Platform

Quantifiable outcome

• ~20x enrichment for successful programs over base rate on historical target-indication phase transitions
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Recursion Pharmaceuticals: Recursion is a leading AI-driven drug discovery company combining high-throughput wet-lab experimentation with ML models to identify novel therapeutics. Like Pheiron, it aims to systematically improve drug program selection through data-driven biology, though Recursion's primary differentiator is high-throughput lab automation rather than multimodal human data analysis.
• Insitro: Insitro uses ML on large-scale biological data (including patient-derived cells and genetics) to predict drug behavior and identify novel therapeutics. Its multimodal data approach and disease-modifying focus directly parallel Pheiron's biological alpha methodology, making it a strong direct competitor in the AI drug discovery space.
• Schrödinger: Schrödinger operates a physics-based computational platform for drug discovery and materials science, serving pharma companies with predictive modeling tools. It is comparable to Pheiron as a B2B platform that helps pharma companies make better program decisions, though its primary methodology is computational chemistry rather than multimodal human data.
• Owkin: Owkin applies AI to multimodal patient data from academic medical centers and hospitals to accelerate drug development and improve clinical trial design. Its federated learning approach to multimodal clinical data mirrors Pheiron's strategy of deriving novel biological evidence from primary multimodal human data analyses.
• Atomwise: Atomwise uses AI for structure-based small molecule drug design, having built AtomNet to predict binding affinity and identify novel compounds. Like Pheiron, it serves biotech and pharma with predictive analytics that aim to reduce late-stage clinical failures through better early-stage decision-making.
• XtalPi: XtalPi combines AI, quantum physics, and cloud computing to accelerate drug discovery and predict small molecule properties. It targets the same enterprise biotech/pharma customer base as Pheiron with predictive models that improve R&D efficiency, though focused on molecular design rather than clinical trial success probability.
• Genesis Therapeutics: Genesis Therapeutics uses AI and molecular simulation to predict drug-target interactions and develop novel therapeutics for undruggable targets. It serves a similar biotech/pharma enterprise customer base with predictive AI infrastructure and pursues a dual model of internal pipeline plus partnerships.

Broad incumbents

• Tempus Labs: Tempus is a much larger precision medicine company that has built one of the world's largest libraries of multimodal clinical and molecular data, and uses AI to enable physicians and pharma to make data-driven decisions. It is comparable as a broad incumbent with overlapping multimodal data assets and pharma services, but operates at much larger scale with diversified offerings beyond clinical trial prediction.

Emerging players

• Benchling: Benchling provides cloud-based software for R&D in life sciences, including notebook, molecular biology, and process development tools. It serves a partially overlapping customer base (biotech R&D teams) with informatics infrastructure that complements Pheiron's predictive analytics, though Benchling focuses on lab data management rather than clinical outcome prediction.
• Lantern Pharma: Lantern Pharma uses its RADR AI platform to identify and develop oncology drug candidates, leveraging ML on multi-omic data to predict drug response. It is comparable as a smaller AI-driven oncology drug developer using data to underwrite biology risk, though more vertically integrated into drug development than Pheiron's primarily platform-focused approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/PheironInc
• LinkedInlinkedin.com/company/pheiron

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pheiron